PFPeptide File
Live Updates
NEWRetatrutide Phase III results — 28.7% body weight reduction confirmed at 12mg/68 weeks·UPDATECJC-1295 half-life study published in Journal of Endocrinology·TRIALBPC-157 human trial enrolment opens Q3 2026·FDARetatrutide NDA submission expected late 2026·RESEARCHNew GLP-1/GIP dual agonist data vs tirzepatide head-to-head·NEWRetatrutide Phase III results — 28.7% body weight reduction confirmed at 12mg/68 weeks·UPDATECJC-1295 half-life study published in Journal of Endocrinology·TRIALBPC-157 human trial enrolment opens Q3 2026·FDARetatrutide NDA submission expected late 2026·RESEARCHNew GLP-1/GIP dual agonist data vs tirzepatide head-to-head·
GLP-1/GIP/Glucagon Triple Agonist

The Retatrutide File

Phase III Clinical Trials · Eli Lilly

Strong Evidence

The most potent weight loss compound in clinical development. Phase III TRIUMPH-4 showed 28.7% body weight reduction at 12mg over 68 weeks.

Mechanism

Triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously

Key Data

weight Loss

28.7% at 12mg/68 weeks (TRIUMPH-4)

trial Program

TRIUMPH (7 Phase III trials)

fda Timeline

NDA expected late 2026–2027

common Side Effects

  • · Nausea
  • · Diarrhea
  • · Vomiting
  • · Dysesthesia (20.9% at 12mg)

Full Article Coming Soon

The full The Retatrutide File will cover mechanism of action, clinical trial evidence, dosage data, side effects, comparisons, and FAQs — all evidence-rated and referenced. Check back soon.

Related Articles

This content is for informational purposes only. Not medical advice. Always consult a qualified healthcare provider before making any health decisions.

The weekly peptide brief.

One email per week. Evidence-rated research summaries on peptides and metabolic science. No hype. No selling. Unsubscribe anytime.

No spam. No selling. Unsubscribe with one click.